• Scalable hiPSC-Derived Human Sensory Neuron Model for HSV-1

  2026-05-23

  This study establishes a robust, scalable protocol for differentiating human inducible pluripotent stem cells (hiPSCs) into sensory neurons suitable for modeling herpes simplex virus 1 (HSV-1) latent infection and reactivation. The findings enable detailed investigation of neuron-intrinsic mechanisms underlying HSV-1 latency in a human context, addressing a critical gap left by animal models.

• Angiotensin Peptides Modulate SARS-CoV-2 Spike–Receptor Bind

  2026-05-22

  This study demonstrates that naturally occurring angiotensin peptides, particularly certain truncated forms, enhance the binding of the SARS-CoV-2 spike protein to its cellular receptors, especially AXL. Findings provide new insight into the interplay between the renin-angiotensin system and COVID-19 pathogenesis, highlighting potential targets for therapeutic intervention.

• QRICH1 Drives ER Stress–Mediated HMGB1 Secretion in HBV Fibr

  2026-05-22

  This study reveals QRICH1 as a pivotal mediator of endoplasmic reticulum (ER) stress that enhances HBV-driven HMGB1 translocation and secretion in hepatocytes, promoting hepatic fibrosis. These findings clarify molecular mechanisms underlying HBV-induced liver injury and provide a foundation for refining experimental fibrosis models.

• RNA Pol II Degradation Triggers Apoptosis Independently of T

  2026-05-21

  Harper et al. (2025) reveal that cell death following RNA Pol II inhibition is not a passive consequence of transcriptional shutdown, but an active, mitochondria-mediated apoptotic response triggered by the loss of hypophosphorylated RNA Pol IIA. This insight reframes how transcriptional inhibitors function in cancer research and highlights a novel pathway for apoptosis induction.

• (-)-JQ1: Precision Control for BET Bromodomain Assays

  2026-05-21

  (-)-JQ1, the gold-standard inactive JQ1 stereoisomer, is essential for dissecting on-target effects in BET bromodomain inhibition studies. Its use as a negative control elevates reproducibility and specificity, especially in complex epigenetics and cancer biology research involving BRD4 pathways.

• ATRX Loss Sensitizes Glioma Cells to RTK and PDGFR Inhibitor

  2026-05-20

  Pladevall-Morera et al. identify that high-grade glioma cells lacking ATRX are more vulnerable to multi-targeted RTK and PDGFR inhibitors, including agents such as Nintedanib. This finding offers a potential stratification strategy for improving therapeutic efficacy in aggressive gliomas and highlights the value of incorporating ATRX mutation status in clinical trial analyses.

• Strategic Use of Aβ42 Peptide: Mechanisms and Translational

  2026-05-20

  This thought-leadership article explores the mechanistic role of Amyloid β-Peptide (1-42) (Aβ42) in Alzheimer's pathology, highlighting its utility in neurotoxicity and microglial activation assays. By bridging molecular insights with strategic guidance, we inform translational researchers on optimizing experimental design, selecting high-quality reagents, and anticipating the next wave of neurodegeneration research.

• HSP90 Inhibition Destabilizes METTL3 and Suppresses MYC in C

  2026-05-19

  This study uncovers a mechanism in which HSP90 stabilizes the m6A methyltransferase METTL3 in colorectal cancer (CRC), thereby promoting MYC expression. Inhibiting HSP90 using 17-AAG accelerates METTL3 degradation, reduces MYC mRNA stability, and impairs cancer cell proliferation, highlighting the HSP90-METTL3 axis as a therapeutic target.

• EZ Cap™ Cas9 mRNA (m1Ψ): Cap1-Structured mRNA for Genome Edi

  2026-05-19

  EZ Cap™ Cas9 mRNA (m1Ψ) is a Cap1-structured, N1-Methylpseudo-UTP-modified mRNA designed for efficient and precise CRISPR-Cas9 genome editing. This reagent enhances mRNA stability, translation efficiency, and suppresses innate immune activation in mammalian cells. APExBIO’s R1014 product is validated for high-specificity gene editing workflows.

• Translating Cathepsin B Inhibition: CA-074 Me in Necroptosis

  2026-05-18

  This thought-leadership article synthesizes mechanistic advances in lysosomal membrane permeabilization, the execution of necroptosis, and the translational potential of CA-074 Me as a cathepsin B inhibitor. It bridges foundational cell death biology with actionable guidance for researchers pursuing apoptosis, lysosomal enzyme inhibition, and inflammation models. Drawing on landmark evidence and building upon prior CA-074 Me-focused content, this piece uniquely situates product intelligence within a rigorous, forward-thinking research strategy.

• Improving In Vitro Evaluation of Anti-Cancer Drug Responses

  2026-05-18

  Schwartz's dissertation advances in vitro drug testing by distinguishing between growth inhibition and cell death, revealing nuanced drug response dynamics in cancer models. These insights refine evaluation strategies for angiogenesis inhibitors and improve translational relevance in preclinical research.

• Transmission Dynamics of Carbapenemase Genes in CREC, China

  2026-05-17

  This study characterizes the molecular epidemiology and transfer mechanisms of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae from Guangdong hospitals during the COVID-19 pandemic. The findings highlight high rates of multidrug resistance and the efficient horizontal spread of resistance genes, informing future surveillance and intervention strategies.

• Ceftolozane/Tazobactam: Novel Strategies Against Resistant G

  2026-05-16

  The reviewed paper details the pharmacological profile, clinical efficacy, and resistance-breaking features of ceftolozane/tazobactam, a new cephalosporin/beta-lactamase inhibitor combination. Its differentiation lies in potent activity against multidrug-resistant gram-negative pathogens, especially Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae, marking significant progress in the management of complicated intraabdominal and urinary tract infections.

• RG108 DNA Methyltransferase Inhibitor: Protocols & Use Cases

  2026-05-15

  RG108 is a benchmark DNA methyltransferase inhibitor for reversible, non-cytotoxic epigenetic modulation in cancer and stem cell research. Explore evidence-based protocols, unique workflow enhancements, and troubleshooting strategies that unlock the full potential of this small molecule for gene regulation studies.

• Sisomicin: Optimizing Aminoglycoside Antibiotic Workflows in

  2026-05-15

  Sisomicin, a potent aminoglycoside antibiotic, excels in both Gram-negative and Gram-positive bacterial infection models by targeting bacterial protein synthesis at the 30S ribosomal subunit. This guide delivers actionable protocols, troubleshooting tips, and workflow enhancements, drawing on the latest in vitro assay innovations and APExBIO’s trusted supply chain.

546 records 17/37 page Previous Next First page 上5页 1617181920 下5页 Last page